Nubeqa Europos Sąjunga - estų - EMA (European Medicines Agency)

nubeqa

bayer ag - darolutamide - prostatic kasvajad, kastreerimine-vastupidavad - endokriinset ravi - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

Intrinsa Europos Sąjunga - estų - EMA (European Medicines Agency)

intrinsa

warner chilcott uk ltd. - testosteroon - seksuaalsed häired, psühholoogilised - suguhormoonid ja genitaalsüsteemi, - intrinsa on näidustatud seksuaalsoov seksuaaliha häire (hsdd) kahe oophorectomised ja hysterectomised (kirurgiliselt indutseeritud menopausi) naistel, kes said samaaegselt östrogeenravi.

Livensa Europos Sąjunga - estų - EMA (European Medicines Agency)

livensa

warner chilcott  deutschland gmbh - testosteroon - seksuaalsed häired, psühholoogilised - suguhormoonid ja genitaalsüsteemi, - livensa on näidustatud seksuaalsoov seksuaaliha häire (hsdd) kahe oophorectomised ja hysterectomised (kirurgiliselt indutseeritud menopausi) naistel, kes said samaaegselt östrogeenravi.

ZYVOXID infusioonilahus Estija - estų - Ravimiamet

zyvoxid infusioonilahus

pfizer europe ma eeig - linesoliid - infusioonilahus - 2mg 1ml 300ml 10tk

LINEZOLID KRKA infusioonilahus Estija - estų - Ravimiamet

linezolid krka infusioonilahus

krka, d.d., novo mesto - linesoliid - infusioonilahus - 2mg 1ml 300ml 1tk

LINEZOLID FRESENIUS KABI infusioonilahus Estija - estų - Ravimiamet

linezolid fresenius kabi infusioonilahus

fresenius kabi polska sp. z o.o. - linesoliid - infusioonilahus - 2mg 1ml 300ml 50tk; 2mg 1ml 300ml 30tk; 2mg 1ml 300ml 10tk

Abiraterone Accord Europos Sąjunga - estų - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - abirateroonatsetaat - eesnäärmevähk - endokriinset ravi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Sogroya Europos Sąjunga - estų - EMA (European Medicines Agency)

sogroya

novo nordisk a/s - somapacitan - kasv - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Abiraterone Krka Europos Sąjunga - estų - EMA (European Medicines Agency)

abiraterone krka

krka, d.d., novo mesto - abirateroonatsetaat - eesnäärmevähk - endokriinset ravi - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Camcevi Europos Sąjunga - estų - EMA (European Medicines Agency)

camcevi

accord healthcare s.l.u. - leuprorelin mesilate - eesnäärmevähk - endokriinset ravi - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.